INTRODUCTION {#s1}
============

Cancer has long been a major public health problem. Currently, it is the leading cause of morbidity and mortality worldwide. In 2016, it is estimated that 1,685,210 new cancer cases and 595,690 cancer deaths will occur in the United States \[[@R1]\], while an estimated 4,292,000 new cancer cases and 2,814,000 cancer deaths were projected in China in 2015 \[[@R2]\]. Various factors contribute to cancer\'s development, with environmental and genetic factors being the most common. In particular, the emergence of high-throughput RNA sequencing (RNA-Seq) technologies have provided a revolutionary means for systematically analysing the role of non-coding genomic transcripts in regulating gene expression, and by extension their impact on disease development and progression. Among these transcripts, long non-coding RNAs (lncRNAs) are emerging as significant regulators in tumourigenesis and progressions \[[@R3], [@R4]\], and numerous lncRNAs have been identified in multiple cancer transcriptomes \[[@R5]\]. One such lncRNA is the imprinted maternally expressed, non-protein coding transcript *H19*. The relationship between an aberrant expression of *H19* and cancer prognosis has been explored by many researchers. Furthermore, a recent meta-analyses performed by Chen et al. has demonstrated that high levels of *H19* expression may serve as a predictive indicator of poor prognoses in multiple cancers. Meta-analysis has also revealed that a high expression of *H19* is significantly related to lymph node metastasis, another influence on cancer prognoses \[[@R6]\].

Recently, genome-wide association study (GWAS) has identified a significant association between the single nucleotide polymorphism (SNP) rs2107425 and breast cancer risk \[[@R7]\]. SNP rs2107425 is located approximately 2 kb upstream of *H19* lncRNA. In 2012, Riaz et al. analysed mRNA expression of the gene *H19* most likely to be closely located to SNP rs2107425 in a subset of 1,401 primary breast tumours. However, no significant difference between the respective three genotype groups of rs2107425 and *H19* mRNA expression was observed \[[@R8]\]. These results indicate that the SNP rs2107425 is unlikely itself to be a causative agent of breast cancer and that a more thorough evaluation of variations in the associated *H19* gene region is warranted. As expected, the associations of *H19* polymorphisms with cancer sensitivities have attracted much interest, with particular focus on *H19* rs2839698 and rs217727. Based on the Encyclopedia of DNA Elements (*ENCODE*) DNase I hypersensitive site (DHS) sequencing data set, we found the two *H19* SNPs (rs2839698 and rs217727) are within open chromatin regions associated with gene regulatory elements, indicating that both of the SNPs may affect the binding of transcription factors. ChIP-Seq data from the ENCODE project further demonstrates that rs217727 is located in a region that may influence the binding of numerous transcription factors. These results show that it is biologically conceivable for the SNPs (rs2839698 and rs217727) in *H19* to be potential causal variants that regulate the expression of *H19* and further affect cancer development and progression.

As expected, the association of two SNPs (rs2839698 and rs217727) together with rs2107425 in *H19* with cancers susceptibility has attracted much interest in subsequent research \[[@R9]--[@R18]\]. Unfortunately, the research exploring this association has not been able to reach a consensus. For instance, a previous study reported that the variant genotype of rs2839698 was definitely associated with increased risk for colorectal and gastric cancers in the Chinese population \[[@R9], [@R11]\]. However, the rs2839698 polymorphism exhibited the opposite associations for cancer risk in Caucasians (a population in the Netherlands) \[[@R14]\]. Thus, we performed a meta-analysis using currently published data to more precisely characterize the associations of rs2107425, rs2839698 and rs217727 in *H19* lncRNA with cancer risks.

RESULTS {#s2}
=======

Characteristics of the published studies {#s2_1}
----------------------------------------

Following the application of strict screening criteria, 10 articles evaluating a total of 13,392 cases and 18,893 controls concerning gastric, bladder, colorectal, breast, ovarian and lung cancers were ultimately included in our quantitative analysis (Figure [1](#F1){ref-type="fig"}). The general characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}. Among these studies, five studies were carried out among Asian populations and five studies were carried out among Caucasian populations. Three articles reported the effects of *H19* polymorphisms in breast cancer, two reported in bladder cancer, two in ovarian cancer, one in gastric cancer, one in lung cancer and one in colorectal cancer. Among the studies that explored the relationships between *H19* SNPs with cancer risk, one focused on 3 SNPs (rs2107425, rs2839698 and rs217727), and four focused on 2 SNPs, while the other five focused on only one SNP. Genotyping was performed using TaqMan in 5 studies, Sequenom in 3 studies, created restriction site PCR (CRS-RFLP) in 1 study, GoldenGate assay in 1 study and PCR-RFLP in 1 study. In addition, there was no evidence to prove that genotype frequencies among the controls deviated from those expected under the Hardy-Weinberg equilibrium (HWE) for each SNP studied. The distributions of genotypes and alleles of *H19* polymorphisms (rs2107425, rs2839698 and rs217727) for each individual study are listed in [Supplementary Tables S2--S4](#SD1){ref-type="supplementary-material"}.

![Flow diagram of the study selection process](oncotarget-07-78631-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  First Author      Year   Country                                             Ethnicity   Type of cancer      Case/Control   Source of controls   Platform                                       Genotyped SNPs
  ----------------- ------ --------------------------------------------------- ----------- ------------------- -------------- -------------------- ---------------------------------------------- --------------------------------
  Hua               2016   China                                               Asian       bladder cancer      1049/1399      Hospital-based       TaqMan                                         rs217727, rs2839698
  Li                2016   China                                               Asian       colorectal cancer   1147/1203      Population-based     TaqMan                                         rs217727, rs2839698
  Xia               2016   China                                               Asian       breast cancer       464/467        Population-based     CRS-RFLP[^a^](#tfn_001){ref-type="table-fn"}   rs217727
  Gong              2016   China                                               Asian       lung cancer         498/213        Hospital-based       Sequenom                                       rs2839698, rs2107425
  Yang              2015   China                                               Asian       gastric cancer      500/500        Hospital-based       TaqMan                                         rs217727, rs2839698
  Butt              2012   Sweden                                              Caucasian   breast cancer       728/1448       Population-based     Sequenom                                       rs2107425
  Barnholtz-Sloan   2010   USA                                                 Caucasian   breast cancer       1972/1776      Population-based     GoldenGate assay                               rs2107425
  Quaye             2009   Multinational[^b^](#tfn_002){ref-type="table-fn"}   Caucasian   ovarian cancer      1491/3145      Population-based     Taqman                                         rs2107425
  Song              2009   Multinational[^c^](#tfn_003){ref-type="table-fn"}   Caucasian   ovarian cancer      5366/8538      Population-based     Taqman + Sequenom                              rs2107425
  Verhaegh          2008   The Netherlands                                     Caucasian   bladder cancer      177/204        Population-based     PCR-RFLP                                       rs217727, rs2839698, rs2107425

created restriction site PCR.

including UK, Denmark and USA.

including European countries, USA and Australia.

Quantitative synthesis {#s2_2}
----------------------

Evaluations of the associations of rs2107425 with cancer risks are presented in Table [2](#T2){ref-type="table"}. The variant T allele of rs2107425 was correlated with a significantly decreased risk of developing cancer (dominant model: OR = 0.86; 95% CI = 0.76--0.98, *P* = 0.005 for the heterogeneity test, *I^2^* = 70.3%; Figure [2](#F2){ref-type="fig"}). The results of other tested models are listed in Table [2](#T2){ref-type="table"}. Next, we evaluated the effect of the rs2107425 polymorphism on cancer risk among the subgroups (Table [2](#T2){ref-type="table"}). In the stratified analyses, associations between rs2107425 and cancer risk were still significant among Caucasians (dominant model: OR = 0.84; 95% CI = 0.74--0.97; *P* = 0.003 for the heterogeneity test, *I^2^* = 75.0%), in studies with population-based controls (dominant model: OR = 0.84; 95% CI = 0.74--0.97; *P* = 0.003 for the heterogeneity test, *I^2^* = 75.0%) and in studies with case sample size ≥ 500 (dominant model: OR = 0.86; 95% CI = 0.74−0.99; *P* = 0.002 for the heterogeneity test, *I^2^* = 79.7%).

###### Summary ORs of the *H19* rs2107425 polymorphism and cancer risk

  Variables              Studies   CT versus CC            TT versus CC   Dominant model                                                                       
  ---------------------- --------- ----------------------- -------------- ---------------- ------------------- ------- ------- ----------------------- ------- --------
  Total                  6         **0.84 (0.73--0.97)**   0.002          73.6%            0.97 (0.89--1.06)   0.798   0.0%    **0.86 (0.76--0.98)**   0.005   70.3%
  *Ethnicity*                                                                                                                                                  
   Asians                1         1.07 (0.75--1.52)                                       0.98 (0.59--1.65)                   1.05 (0.75--1.47)               
   Caucasians            5         **0.82 (0.71--0.96)**   0.001          77.5%            0.97 (0.89--1.06)   0.671   0.0%    **0.84 (0.74--0.97)**   0.003   75.0%
  *Cancer type*                                                                                                                                                
   breast cancer         2         0.84 (0.58--1.23)       0.014          83.4%            0.94 (0.79--1.12)   0.329   0.0%    0.85 (0.60--1.20)       0.016   82.6%
   ovarian cancer        2         0.82 (0.65--1.04)       0.002          89.2%            0.98 (0.89--1.09)   0.268   18.4%   0.84 (0.68--1.05)       0.003   88.6%
   lung cancer           1         1.07 (0.75--1.52)                                       0.98(0.59--1.65)                    1.05 (0.75--1.47)               
   bladder cancer        1         0.66 (0.43--1.01)                                       1.02 (0.51--2.03)                   0.72 (0.48--1.07)               
  *Source of controls*                                                                                                                                         
   Population-based      5         **0.82 (0.71--0.96)**   0.001          77.5%            0.97 (0.89--1.06)   0.671   0.0%    **0.84 (0.74--0.97)**   0.003   75.0%
   Hospital-based        1         1.07 (0.75--1.52)                                       0.98 (0.59--1.65)                   1.05 (0.75--1.47)               
  *Case sample size*                                                                                                                                           
   ≥ 500                 4         **0.84 (0.72--0.98)**   0.001          81.2%            0.97 (0.89--1.06)   0.506   0.0%    **0.86 (0.74--0.99)**   0.002   79.7%
   \< 500                2         0.88 (0.67--1.15)       0.085          66.30%           0.99 (0.66--1.51)   0.934   0.00%   0.90 (0.69--1.16)       0.154   50.90%

*P* for heterogeneity (a random-effects model was used when the *P* value for heterogeneity test was \< 0.05; otherwise, a fixed-effect model was used).

![Forest plot of OR with 95%CI for the *H19* rs2107425 with cancer risk under dominant model](oncotarget-07-78631-g002){#F2}

The evaluations of the associations of rs2839698 with cancer risks are presented in Table [3](#T3){ref-type="table"}. The variant A allele exhibited a marginally significant association with cancer risk in the dominant model (OR = 1.09; 95% CI = 0.99−1.20, *P* = 0.113 for the heterogeneity test, *I^2^* = 46.5%; Figure [3](#F3){ref-type="fig"}). The results of other tested models are listed in Table [3](#T3){ref-type="table"}.

###### Summary ORs of the *H19* rs2839698 polymorphism and cancer risk

  Variables                      Studies   CT versus CC            TT versus CC   Dominant model                                                                           
  ------------------------------ --------- ----------------------- -------------- ---------------- ----------------------- ------- ------- ----------------------- ------- -------
  Total                          5         1.07 (0.96--1.18)       0.130          43.8%            1.15 (0.83--1.58)       0.019   66.1%   1.09 (0.99--1.20)       0.113   46.5%
  *Ethnicity*                                                                                                                                                              
   Asians                        4         1.09 (0.98--1.21)       0.396          0.0%             1.15 (0.78--1.69)       0.008   74.4%   **1.11 (1.01--1.23)**   0.158   42.3%
   Caucasians                    1         0.65 (0.40--1.06)                                       1.10 (0.63--1.92)                       0.78 (0.50--1.22)               
  *Cancer type*                                                                                                                                                            
   digestive system cancer ^b^   2         **1.17 (1.02--1.35)**   0.594          0.0%             **1.58 (1.22--2.05)**   0.840   0.0%    **1.23 (1.08--1.41)**   0.546   0.0%
   bladder cancer                2         0.94 (0.80--1.10)       0.123          58.0%            1.03 (0.79--1.36)       0.807   0.0%    0.96 (0.82--1.11)       0.340   0.0%
   lung cancer                   1         1.15 (0.81--1.63)                                       0.60 (0.35--1.04)                       1.01 (0.73--1.40)               
  *Source of controls*                                                                                                                                                     
   Population-based              2         0.91 (0.53--1.55)       0.032          78.2%            **1.43 (1.08--1.88)**   0.290   10.9%   1.14 (0.98--1.33)       0.076   68.2%
   Hospital-based                3         1.06 (0.93--1.21)       0.284          20.6%            1.02 (0.62--1.67)       0.019   74.7%   1.06 (0.94--1.20)       0.149   47.6%
  *Case sample size*                                                                                                                                                       
   ≥ 500                         3         1.09 (0.97--1.21)       0.237          30.5%            **1.32 (1.08--1.61)**   0.096   57.3%   **1.12 (1.01--1.24)**   0.089   58.7%
   \< 500                        2         0.95 (0.72--1.25)       0.063          71.1%            0.81 (0.55--1.20)       0.133   55.7%   0.92 (0.71--1.20)       0.357   0.0%

*P* for heterogeneity (a random-effects model was used when the *P* value for heterogeneity test was \< 0.05; otherwise, a fixed-effect model was used).
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Next, we evaluated the effect of the rs2839698 polymorphism on cancer risk among the subgroups (Table [3](#T3){ref-type="table"}). In the stratified analyses, the rs2839698 SNP had significant association with increased cancer risk among Asians (Chinese; dominant model: OR = 1.11; 95% CI = 1.01--1.23; *P* = 0.158 for the heterogeneity test, *I^2^* = 42.3%). Beyond that, the rs2839698 variant exhibited a significant association with an increased risk of digestive system cancers (dominant model: OR = 1.23; 95% CI = 1.08--1.41; *P* = 0.546 for the heterogeneity test, *I^2^* = 0.0%). Interestingly, the variant A allele of rs2839698 was significantly associated with an increased risks of developing cancer among studies with a case sample size ≥ 500 (dominant model: OR = 1.12; 95% CI = 1.01−1.24; *P* = 0.089 for the heterogeneity test, *I^2^* = 58.7%).

The evaluations of the associations between SNP rs217727 and cancer risk are displayed in Figure [4](#F4){ref-type="fig"}. Overall, the A variant allele of rs217727 exhibited no significant association with cancer risks (dominant model: OR = 0.94; 95% CI = 0.78--1.12, *P* = 0.018 for the heterogeneity test, *I^2^* = 66.3%). The results of other tested models are listed in Table [4](#T4){ref-type="table"}. In further stratified analyses, rs217727 SNP was significantly associated with decreased cancer risk among studies with population-based controls (dominant model: OR = 0.82; 95% CI = 0.72−0.94; *P* = 0.739 for the heterogeneity test, *I^2^* = 0.0%). Additionally, the variant A allele of rs217727 was significantly associated with a decreased risk of developing cancer among studies with a case sample size \< 500 (dominant model: OR = 0.78; 95% CI = 0.62--0.98; *P* = 0.636 for the heterogeneity test, *I^2^* = 0.0%; Table [4](#T4){ref-type="table"}).
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###### Summary ORs of the *H19* rs217727 polymorphism and cancer risk

  Variables                     Studies   GA versus GG            AA versus GG   Dominant model                                                                            
  ----------------------------- --------- ----------------------- -------------- ---------------- ----------------------- ------- -------- ----------------------- ------- -------
  Total                         5         0.88 (0.73--1.06)       0.022          65.0%            1.10 (0.83--1.48)       0.011   69.5%    0.94 (0.78--1.12)       0.018   66.3%
  *Ethnicity*                                                                                                                                                              
   Asians                       4         0.90 (0.73--1.11)       0.014          71.9%            1.16 (0.87--1.54)       0.012   72.7%    0.97 (0.80--1.17)       0.018   70.3%
   Caucasians                   1         0.74 (0.49--1.14)                                       0.45 (0.13--1.50)                        0.71 (0.47--1.08)               
  *Cancer type*                                                                                                                                                            
   digestive system cancer^b^   2         1.02 (0.71--1.47)       0.024          80.4%            1.16 (0.57--2.34)       0.002   89.3%    1.05 (0.67--1.64)       0.004   88.0%
   bladder cancer               2         0.90 (0.77--1.06)       0.331          0.0%             1.20 (0.93--1.54)       0.100   63.0%    0.95 (0.82--1.11)       0.143   53.5%
   breast cancer                1         0.64 (0.47--0.87)                                       1.11 (0.79--1.55)                        0.81 (0.61--1.06)               
  *Source of controls*                                                                                                                                                     
   Population-based             3         **0.79 (0.69--0.91)**   0.256          26.6%            0.90 (0.74--1.09)       0.192   39.4%    **0.82 (0.72--0.94)**   0.739   0.0%
   Hospital-based               2         1.01 (0.88--1.17)       0.080          67.3%            **1.38 (1.11--1.71)**   0.221   33.3%    1.08 (0.94--1.24)       0.061   71.6%
  *Case sample size*                                                                                                                                                       
   ≥ 500                        3         0.95 (0.85--1.06)       0.076          61.1%            1.18 (0.80--1.75)       0.004   81.8%    1.02 (0.81--1.28)       0.015   76.2%
   \< 500                       2         **0.67 (0.53--0.86)**   0.571          0.0%             1.03 (0.75--1.42)       0.156   50.30%   **0.78 (0.62--0.98)**   0.636   0.0%

*P* for heterogeneity (a random-effects model was used when the *P* value for heterogeneity test was \< 0.05; otherwise, a fixed-effect model was used).

Test of heterogeneity {#s2_3}
---------------------

For rs217727, significant heterogeneity was observed after the data were pooled (dominant model: *P* for heterogeneity = 0.018, *I^2^* = 66.3%). As shown in Table [4](#T4){ref-type="table"}, when the subjects were stratified on the basis of ethnicity, heterogeneity remained in Asians (dominant model: *P* for heterogeneity = 0.018, *I^2^* = 70.3%). Additionally, in analyses of control sources, the heterogeneity disappeared in studies with population-based controls (dominant model: *P* for heterogeneity = 0.739, *I^2^* = 0.0%), as well as in hospital-based controls (dominant model: *P* for heterogeneity = 0.061, *I^2^* = 71.6%). Furthermore, heterogeneity disappeared in studies with a case sample size \< 500 (dominant model: *P* for heterogeneity = 0.636, *I*^2^ = 0.0%). Nonetheless, heterogeneity was still present in studies with a case sample size ≥ 500 (dominant model: *P* for heterogeneity = 0.015, *I*^2^ = 76.2%).

Sensitivity analysis {#s2_4}
--------------------

To test the stability of the rs217727 results, we conducted sensitivity analyses by sequentially removing each eligible study ([Supplementary Table S5](#SD1){ref-type="supplementary-material"}). A study by Yang et al. that focused on gastric cancer was the major contributor of heterogeneity in the dominant model (*I^2^* = 66.3%, *P* for heterogeneity = 0.018). After removing this study, heterogeneity was significantly reduced (*I^2^* = 19.90%, *P* for heterogeneity = 0.290). As expected, similar results were observed in other genetic models (i.e., GA versus GG and AA versus GG), indicating that Yang et al.\'s study on gastric cancer markedly changed the pooled OR.

Publication bias {#s2_5}
----------------

We utilized funnel plots and Begg\'s test to evaluate potential publication biases in the selected literature. As illustrated in [Supplementary Figures S1--S3](#SD1){ref-type="supplementary-material"}, the shapes of the funnel plots were symmetrical. Moreover, a Begg\'s test provided further statistical evidence for the absence of publication bias (*P* = 0.57 for rs2107425, *P* = 1.00 for rs2839698, and *P* = 0.62 for rs217727).

DISCUSSION {#s3}
==========

In the current study, we performed a meta-analysis by pooling 10 studies with totals of 13,392 cases and 18,893 controls. We demonstrated that the variant T allele of rs2107425 exhibited a significant decreased risk for developing cancer, and the A allele of rs2839698 was associated with a significant increased cancer risk in Asians, as well as a significant association with an increased risk for digestive system cancers. In contrast, the rs217727 variant allele exhibited no significant association with cancer risks.

Recently, multiple studies have reported the significant role of *H19* in tumourigenesis. As suggested by Chen et al. in 2016, *H19* may promote gastric cancer cell migration and invasion \[[@R19]\], while similar results were observed in oesophageal squamous cell carcinoma cells \[[@R20], [@R21]\]. Our study indicates that *H19* may act as an oncogene and predict poor prognosis. Furthermore, bioinformatic analysis has shown that rs2839698 in *H19* may change crucial folding structures and alter the targeted microRNAs \[[@R11]\]. Using the prediction of the miRNA-binding analysis website (<http://bioinfo.life.hust.edu.cn/miRNASNP2/index.php>), we found that rs2839698 polymorphism in *H19* 3′ UTR may result in the loss of hsa-miR-24-1-5p and hsa-miR-24-2-5p function. MiR-24 acts as a tumour suppressor and is low-expressed in various types of cancers, including colorectal, prostate and bladder cancer \[[@R22]--[@R24]\]. Thus, it is biologically conceivable that the loss of miR-24 function owing to a SNP rs2839698 in the 3′ UTR of *H19* may give rise to overexpression of *H19* and thereby promote proliferation, migration and invasion of some cancer cells. However, experimental studies to evaluate the limits of this hypothesis are warranted, and future functional studies are required to clarify the possible mechanisms.

In this meta-analysis, we identified a marginally significant relationship of rs2839698 SNP with overall cancer risk. According to a stratified analysis, SNP rs2839698 was definitely associated with an increased risk of developing cancer for Asians (mainly Chinese patients). By contrast, among a population in the Netherlands, the same variant genotype of rs2839698 exhibited no significant association with cancer risk, and the effect value was even in the opposite direction relative to previous studies of Chinese populations. There are several possible reasons for different results between Asians and Caucasians. First, the difference may have resulted from differences in the genetic backgrounds of the studied populations. For instance, based on the HapMap data (International HapMap Project), the A allele frequency of the rs2839698 SNP is 0.28 in Asian populations (CHB+JPT) and 0.55 in European populations (CEU). Second, differences may stem from the utilization of different genotyping methods including PCR-RFLP, CRS-RFLP, TaqMan and Sequenom. Third, when compared with Asian populations, the sample sizes of the Caucasian populations might not have been sufficiently large to reach a convincing conclusion concerning the association of the rs2839698 SNP with cancer risks. Additionally, the different types of cancers involved and random errors may also have been potential reasons for different findings between Asians and Caucasians.

The sensitivity analysis of rs217727 found that the result of pooling ORs was significantly changed once Yang et al.\'s study was excluded. This change could be accounted for by the 500 mixed types of gastric cancer patients (221 cardia gastric cancer patients and 279 non-cardia gastric cancer patients) enrolled in Yang et al.\'s study, in contrast to the stricter criteria used for recruiting patients into other studies. To account for this difference, we separated Yang et al.\'s study into two parts (cardia gastric cancer and non-cardia gastric cancer), and re-performed the meta-analysis with each part considered separately. Interestingly, heterogeneity obviously decreased when Yang et al.\'s study was confined to non-cardia gastric carcinoma (dominant model: *P* for heterogeneity = 0.062, *I^2^* = 55.4%). However, when Yang et al.\'s study was confined to cardia gastric carcinoma patients, heterogeneity was still present (dominant model: *P* for heterogeneity = 0.043, *I^2^* = 59.3%). So these conclusions should be considered cautiously.

The strength of our meta-analysis stems from systematically reviewing the relationships between three *H19* polymorphisms (rs2107425, rs2839698 and rs217727) and cancer susceptibility for the first time. In addition, the well-designed search and selection methods significantly increased the statistical power of this meta-analysis. However, there are also some limitations that need to be addressed. First, significant heterogeneity between the studies was observed for the analyses of rs2107425 and rs217727. Among the 10 published studies contained in our meta-analysis, some studies were population-based, while others were hospital-based. Second, in some studies, detailed information (e.g., age, gender, smoking status, and alcohol consumption) was not provided, which further limited the stratification analyses. Moreover, if we had been able to acquire more detailed information, we would have been able to achieve more precise estimations by adjusting for other potential covariates. Finally, few studies were included in this meta-analysis, and this small sample size limits the power to detect the associations. Because the power of funnel plots and Begg\'s test of publication bias may also greatly constrain our analysis, our conclusions should be interpreted cautiously. Well-conducted studies with larger sample sizes are needed to further explore the cancer risks related to *H19* SNPs, especially in Caucasians.

MATERIALS AND METHODS {#s4}
=====================

Identification and eligibility criteria of relevant studies {#s4_1}
-----------------------------------------------------------

A comprehensive literature search of research published before July 31, 2016 was performed using PubMed and Web of Science using the following keywords: ("*H19*"), ("cancer", "carcinoma", "tumor", "tumour", or "neoplasm") and ("polymorphism", "variation", "variant", or "mutation"). Only available full-text articles written in English were included in this meta-analysis. The references in the retrieved articles were also reviewed for possible inclusion. Studies were included if they met the following eligibility criteria: (1) case-control studies focused on the relationship between *H19* polymorphisms and any type of cancer, (2) at least two articles for each studied *H19* polymorphism, and (3) available information concerning the genotype frequency of each included *H19* SNP (i.e., rs2107425, rs2839698 or rs217727). The exclusion criteria were as follows: (1) Studies that did not focus on cancer risk, (2) did not study *H19* SNPs (rs2107425, rs2839698 or rs217727), (3) did not report the relevant genotype frequency data, (4) were not published in English, or (5) non-human research was involved. Finally, a total of 10 articles containing 13,392 cases and 18,893 controls were included in this meta-analysis (Figure [1](#F1){ref-type="fig"}).

Data extraction {#s4_2}
---------------

Two investigators (M.C. and L.M.) independently extracted the data and agreed on the criteria and selections. Each article was mined for the following information: year of publication; name of the first author, ethnicity and country of origin; the type of cancer studied; the numbers of cases and controls; the source of controls; genotyping platform; and genotyped SNPs. We categorized ethnicities either as Caucasian or Asian.

Quality assessments of the included studies {#s4_3}
-------------------------------------------

The methodological quality of each included study was evaluated using the Newcastle-Ottawa quality assessment scale (NOS). Using this method, each study was judged on standard criteria and subsequently categorized based on three factors: selection, comparability, and exposure. Summary scores ranging from 0 to 9 points were calculated, where higher scores indicate lower risks of bias ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

Statistical analysis {#s4_4}
--------------------

The risk of cancer associated with each *H19* polymorphism was estimated in each study using the odds ratio (OR) and its 95% confidence interval (95% CI). The between-study heterogeneity was examined with a chi-square-based *Q* statistic test, with *P* ≤ 0.05 considered as statistically significant. When heterogeneity between studies was absent we pooled the results using fixed-effect models. Otherwise, a random-effects model was chosen. Subsequently, we evaluated the risks of heterozygous and variant homozygous genotypes relative to the wild-type homozygous genotype, and then assessed the risks of the combined heterozygous as well as variant homozygous genotypes relative to the wild-type homozygous genotype while assuming the dominant effects of the variant allele. We performed a stratification analysis based on ethnicity (divided into Caucasians and Asians), cancer type, source of controls and case sample size. Funnel plots and Begg\'s test were utilized to evaluate publication bias. All analyses were performed using Stata software, version 12.0 (Stata Corporation, College Station, TX, and USA).

CONCLUSIONS {#s5}
===========

This meta-analysis provided evidence that *H19* rs2107425 may modify general cancer susceptibility, while rs2839698 may modify cancer susceptibility based on ethnicity and type. Beyond these conclusions, we believe further studies that incorporate subjects from different ethnic backgrounds combined with re-sequencing the marked regions and functional evaluations are warranted.
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